Coalition for Epidemic Preparedness Innovations (CEPI), Oslo, Norway.
Coalition for Epidemic Preparedness Innovations (CEPI), Oslo, Norway; University of Applied Sciences & Arts, Hanover, Germany.
Lancet Infect Dis. 2022 Jan;22(1):e13-e27. doi: 10.1016/S1473-3099(21)00400-X. Epub 2021 Nov 1.
Henipaviruses, including Nipah virus, are regarded as pathogens of notable epidemic potential because of their high pathogenicity and the paucity of specific medical countermeasures to control infections in humans. We review the evidence of medical countermeasures against henipaviruses and project their cost in a post-COVID-19 era. Given the sporadic and unpredictable nature of henipavirus outbreaks, innovative strategies will be needed to circumvent the infeasibility of traditional phase 3 clinical trial regulatory pathways. Stronger partnerships with scientific institutions and regulatory authorities in low-income and middle-income countries can inform coordination of appropriate investments and development of strategies and normative guidelines for the deployment and equitable use of multiple medical countermeasures. Accessible measures should include global, regional, and endemic in-country stockpiles of reasonably priced small molecules, monoclonal antibodies, and vaccines as part of a combined collection of products that could help to control henipavirus outbreaks and prevent future pandemics.
亨尼帕病毒，包括尼帕病毒，被认为是具有显著流行潜力的病原体，因为它们具有很高的致病性，而针对人类感染的特异性医疗对策却很少。我们回顾了针对亨尼帕病毒的医疗对策的证据，并预测了在 COVID-19 之后时代的成本。鉴于亨尼帕病毒爆发的零星和不可预测性质，需要创新策略来规避传统的 3 期临床试验监管途径的不可行性。与低收入和中等收入国家的科学机构和监管当局建立更紧密的伙伴关系，可以为协调适当投资以及制定和规范准则提供信息，以部署和公平使用多种医疗对策。可获得的措施应包括全球、区域和地方性国家储备合理价格的小分子、单克隆抗体和疫苗，作为有助于控制亨尼帕病毒爆发和预防未来大流行的产品组合的一部分。
